

▪ MB49 cells

Mouse MB49 cells are derived from C57BL/6 bladder epithelial cells transformed by a carcinogenic agent (DMBA).

▪ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of C57BL/6 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing MB49 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the MB49 cells as subcutaneous tumours

Mean \pm SEM (n=4; take rate 100%)

▪ Drug Responses

Anti-PD1 12.5 mg/kg \rightarrow Response

Anti-PDL1 12.5 mg/kg \rightarrow Response

Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.

Antineo has developed models of secondary resistance to anti-PD1 or anti-PDL1 (ID MB49 anti-PD1R and MB49 anti-PDL1R). These models have been developed *in vivo* without genetic modifications.